Hey readers! Here's an unusual twist in how new tech reaches you: the FDA has decided to let a glucose program go live with Medicare patients before signing off on that specific use, on the condition that the maker keep collecting real-world data. It's a notable shift in the regulator's playbook, and this week we unpack what it means, plus a wave of teplizumab news, some sharp pump updates, and a sobering trial result.
🔬 The FDA's new front door for digital health
FDA picks Dexcom for TEMPO pilot, skipping premarket review reports that the FDA has named Dexcom as the first manufacturer in its Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot, letting participating digital health devices reach Medicare patients without prior FDA authorization for that specific use. – The Next Web
The mechanism here matters. The FDA calls it enforcement discretion: the agency agrees not to enforce premarket authorization requirements as long as manufacturers collect and share real-world data on how the device actually performs. In practice, that flips the usual order. Instead of proving a device out in a prospective trial first and then reaching patients, the device reaches patients and generates the evidence as it goes.
FDA taps Dexcom as first participant in digital health pilot fills in what Dexcom is actually bringing: the Glucose Health Program, which combines Dexcom G7 continuous glucose monitoring data and Stelo glucose biosensor data with artificial intelligence to support prediabetes and type 2 diabetes care and to monitor metabolic and nutritional status. – MobiHealthNews
The evaluation runs within the CMS Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model, focused on early cardio-kidney-metabolic conditions. The FDA frames it as a voluntary, risk-based approach where marketing authorization gets pursued afterward, as appropriate. Michelle Tarver, director of the FDA's Center for Devices and Radiological Health, put the intent this way:
"For the millions of Americans living with chronic conditions, access to the right technology at the right time can be life-changing."
Why this deserves your attention: the whole model rests on real-world evidence rather than the FDA's historical reliance on prospective trials. That's a meaningful test of whether messier, day-to-day data can carry the same regulatory weight. The Next Web notes a law firm described TEMPO as a potential CMS-linked "side door," with open questions about the scope of oversight, and the FDA itself cautions that participating does not signal any future marketing-approval decision. Outcomes are unspecified if the real-world data turns out inconclusive. For people who rely on CGM data being rigorously vetted, it's worth watching how much evidence this approach ultimately produces, and how it's judged. CMS deputy administrator Abe Sutton framed the pairing as a way to reward outcomes over individual services:
"ACCESS provides a clear payment pathway that rewards measurable improvements in patient health rather than individual services, while TEMPO helps generate the real-world evidence needed to evaluate promising new technologies responsibly."
One more thing to sit with: real-world data isn't a novelty in diabetes tech. It's already shaping how devices get judged after launch, which brings us to the next story.
💉 Pumps and access moves
MiniMed Flex Insulin Pump Access Expands to Medicare Users reports that Medicare and Medicare Advantage beneficiaries now have access to the MiniMed Flex, an app-controlled pump about half the size of the 780G that holds 300 units and uses SmartGuard to adjust insulin every five minutes. – Diabetech
Here's the real-world-data connection: findings presented at the ADA Scientific Sessions 2026 reported that Medicare beneficiaries using the MiniMed 780G exceeded ADA-recommended glycemic targets. That's exactly the kind of post-market evidence TEMPO is betting on. MiniMed Flex currently pairs with the Simplera Sync sensor, with Abbott's Instinct sensor compatibility expected later in summer 2026. Further out, the company is developing the tubeless MiniMed Fit (planned fall 2026 regulatory submission) and Vivera, a fully closed-loop algorithm that would make meal-time announcements optional.
Clinical utility of the twiist Automated Insulin Delivery System covers an 8-week single-center study of the twiist AID system in 20 adults with type 1 diabetes. – Sugar is a DRUG
At 8 weeks, 19 completers logged a mean time in range of 70.3±15.5%, and HbA1c dropped 0.4%±0.5% among those starting above 7%, with no serious adverse events. The standout detail: twiist detected 67 occlusion events across 15 participants within 30 minutes of rising glucose, which points to a safety feature worth larger, longer study.
Medtrum Advances 300U Tubeless Patch Pump Toward German Launch: Medtrum's 300-unit tubeless patch pump, part of its TouchCare Nano System, was listed in Germany's statutory health insurance medical aids directory with a reimbursement code, offering 50% more capacity than typical 200U pumps for people with larger insulin needs.
🧬 Teplizumab keeps making headlines
The drug known as teplizumab (branded Tzield) showed up in three separate reports this week, which tells you how much regulatory momentum it's carrying globally.
FDA Approves TZIELD: A Breakthrough for Type 1 Diabetes Treatment reports that on July 26, 2026, MacroGenics announced FDA accelerated approval of TZIELD for children aged eight to 17 with stage 3 type 1 diabetes, where the monoclonal antibody is meant to delay the decline of insulin production. – mypenstrustfunz
MacroGenics also reported a $24.5 million regulatory milestone payment from Sanofi, with eligibility for up to $305 million more under their agreement. The framing is disease-modifying: aiming at the underlying progression rather than only managing symptoms.
Breakthrough in Type 1 Diabetes Treatment: Tzield Approved in Australia reports Australia has approved Tzield for early-stage type 1 diabetes, describing it as potentially delaying the need for insulin therapy by an average of two years. – proabort
The access catch: Tzield is available to Australians with stage 2 type 1 diabetes but is not listed on the Pharmaceutical Benefits Scheme, which the article says may limit who can actually get it.
Breakthrough Drug Delays Type 1 Diabetes Onset: This piece reports teplizumab can postpone onset for up to three years in high-risk individuals and notes Sanofi has secured a discounted NHS arrangement aimed at fairer access.
The throughline across all three: approvals are landing, but affordability and listing decisions will decide whether eligible families can reach the drug.
🛡️ Prevention research: wins and honest losses
Diamyd Medical Provides Update on Learnings from DIAGNODE-3 Interim Analysis reports that the pivotal Phase 3 DIAGNODE-3 trial of retogatein did not achieve statistical significance at its pre-specified interim analysis (174 of 321 participants at 15 months), and the company is closing it for futility. – Placera
No new safety concerns emerged, and the review didn't pin down a single cause. Instead it flagged hypothesis-generating factors, including the operational demands of intralymphatic administration, the possibility that earlier timing after diagnosis matters, and lower drug-product potency than in the earlier DIAGNODE-2 study.
"DIAGNODE-3 did not meet the pre-specified criteria required to continue, and we are acting on that result with scientific discipline and financial responsibility."
Negative trials are part of how the field learns, and this one at least leaves clear questions for the next generation of antigen-specific tolerization studies.
Help us find out if a low dose immunotherapy can STOP-T1D: TrialNet's STOP-T1D study is enrolling 114 participants ages 12 to 35 to test whether low-dose anti-thymocyte globulin can delay or prevent stage 3 T1D, and notes that for people in T1D research, DKA risk at diagnosis drops from 30% to 3%.
Baby Elizabeth joins trial at Addenbrooke's: The AVAnT1A trial is testing whether Covid-19 vaccination in infants at high genetic risk can reduce early development of type 1 diabetes, following participants until age six.
🔎 Also worth your time
New wearable ring tracks glucose, ketone and other biomarkers in sweat: UC San Diego engineers built a smart ring whose glucose readings closely tracked commercial CGMs and whose ketone readings matched blood meters, drawing sweat passively via an osmotic hydrogel.
Comparison of AID users and non-users regarding glycemic control and diabetes distress: In 169 adults with T1D, AID users reported significantly lower HbA1c and lower diabetes distress, with the biggest differences in Management Distress and Powerlessness, a reminder to measure psychosocial burden alongside numbers.
Type 1 Diabetes-Induced Kidney Disease Treated with Phase III Trial Drug: An ATTEMPT trial subset (98 participants aged 12 to 21) found dapagliflozin reversed molecular hallmarks of kidney damage and eased hyperfiltration in adolescents with T1D.
Efforts Address Immune Suppression in Islet Cell Transplants: An ADA 2026 pilot (n=12) swapped tacrolimus for the less-toxic antibody tegoprubart, with participants remaining insulin independent, and a separate NEJM letter reported a genetically modified islet transplant functioning at 14 months without immune suppression.
That's the issue. The Dexcom TEMPO news is the one to keep an eye on, because how the FDA judges its real-world evidence could shape the on-ramp for the next generation of devices you'll actually use. Take care of yourselves, and we'll see you next time.